investor login

contact

team

dedicated funds

news

 portfolio

Ten63 Therapeutics is focused on improving human health by developing better, more durable therapeutics against cancer and some of the world’s most lethal diseases. We are leveraging our proprietary in silico platform BEYOND to generate novel therapeutics to hit previously undruggable targets while bringing the paradigm of durable response into early drug design through our unique ability to predict and overcome drug resistance.

VISIT WEBSITE

 

Active, Bio Tech, HVP VII

back to portfolio

contact

© hatteras venture partners | all rights reserved | terms + privacy | site credit

 team

 portfolio

news

home

Hatteras Venture Partners is a venture capital firm that builds transformational companies in areas of health innovation.

dedicated funds

contact

 team

dedicated funds

news

home

 portfolio